CJC-1295 (no dac) 5mg + Ipamorelin 5mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of CJC-1295 (no DAC) / Ipamorelin Blend supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025021

Key analytical results include:

• Ipamorelin Assay Content: 4.56 mg
• Ipamorelin Identification – Retention Time: 0.989
• Ipamorelin Identification – Spectrum: 991
• Ipamorelin Purity: greater than 99.8 percent
• CJC-1295 (MOD GRF 1-29) Assay Content: 5.15 mg
• CJC-1295 Identification – Retention Time: 0.992
• CJC-1295 Identification – Spectrum: 982
• CJC-1295 Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

CJC-1295 (no DAC) / Ipamorelin is a dual-peptide research preparation combining two synthetic peptides frequently studied in laboratory environments investigating endocrine signalling and peptide-receptor interaction systems.

The formulation contains CJC-1295 without DAC (also known as MOD GRF 1-29), a growth hormone releasing hormone analogue, combined with Ipamorelin, a selective peptide studied in relation to growth hormone secretagogue receptor signalling pathways.

This preparation contains a combined 10 mg of high purity lyophilized peptide material supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the peptides for controlled in vitro experimentation.

Because of their defined peptide structures and stable analytical profiles, CJC-1295 (no DAC) and Ipamorelin are widely referenced in experimental research exploring endocrine regulatory systems and peptide-mediated receptor interactions.

Compound Overview

CJC-1295 (no DAC), also known as MOD GRF (1-29), is a modified analogue of growth hormone releasing hormone designed for research exploring receptor-mediated endocrine signalling.

Ipamorelin is a synthetic pentapeptide investigated in biochemical research environments for its interaction with growth hormone secretagogue receptors.

Both peptides are frequently studied in laboratory models examining peptide-hormone signalling networks and receptor-mediated cellular responses.

The combination of these peptides within a single preparation allows researchers to investigate comparative peptide signalling behaviour and interaction dynamics in controlled experimental systems.

Historical Background and Scientific Context

Scientific interest in hormone-regulating peptides expanded significantly during the late twentieth century as researchers began mapping endocrine signalling systems at the molecular level.

Growth hormone releasing hormone analogues such as MOD GRF (1-29) were developed as experimental tools to study hormonal regulatory mechanisms and receptor signalling processes.

Secretagogue peptides such as Ipamorelin were later introduced in laboratory research to investigate receptor-mediated peptide signalling and endocrine pathway regulation.

Modern research frequently examines combinations of peptides to explore complex signalling interactions within endocrine regulatory networks.

Mechanistic Focus in Research

Within experimental laboratory environments, CJC-1295 (no DAC) / Ipamorelin blends are studied in relation to endocrine signalling and peptide-receptor interaction pathways.

Research investigations commonly explore these peptides in experimental models examining:

• Growth hormone releasing hormone receptor signalling
• Growth hormone secretagogue receptor interaction
• Peptide-mediated endocrine signalling pathways
• Hormonal regulatory network modelling
• Intracellular signalling cascade analysis
• Comparative peptide interaction studies
• Peptide-receptor activation mechanisms

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing endocrine signalling and receptor-mediated peptide interactions.

Research Applications

In controlled research environments, CJC-1295 (no DAC) / Ipamorelin blends may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated receptor pathways.

Examples of research applications include:

• Endocrine signalling pathway investigation
• Peptide-receptor interaction research
• Hormonal regulatory mechanism studies
• Cell signalling analysis
• Comparative peptide interaction modelling
• Molecular endocrine pathway research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Above 99.8 percent purity for both peptides
• No detectable heavy metals or microbial contamination
• Endotoxin below 0.001 EU per mg
• Batch GF082025021 – Published August 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.